Recently Featured

BMS’ Sotyktu secures EC approval for psoriatic arthritis

May 12, 2026
Bristol Myers Squibb (BMS) has received approval from the European Commission for Sotyktu (deucravacitinib) as a treatment for active psoriatic arthritis (PsA). This milestone not only enhances BMS’s portfolio in the immunology space but also signifies a growing recognition of targeted therapies in managing chronic inflammatory conditions. PsA, affecting a significant portion of the population,…

The capacity crunch in biopharma is a location problem

May 12, 2026
Cell and gene therapies are facing significant limitations, not due to a lack of innovative ideas, but rather because of geographical constraints in manufacturing capabilities. The emergence of “ready-now” locations is reshaping the landscape for scaling these advanced therapies, allowing companies to expedite production timelines and meet growing market demands. This shift highlights the critical…

OVID Health Appoints Davide Scalenghe to Enhance Global Strategy

May 12, 2026
OVID Health has appointed Davide Scalenghe, the former global public health lead at Edelman, to spearhead its international strategy and partnerships. This strategic hire comes as OVID aims to strengthen its global presence in the competitive healthcare landscape. Scalenghe brings a wealth of experience in public health communications and strategic partnerships, which are critical in…

New Gene Therapy Trials Offer Hope for Rare Disease Community After Five-Year Setback

May 12, 2026
Five years after a significant setback in gene therapy for myotubular myopathy, a renewed clinical trial has emerged, providing fresh hope for affected families. The National Institutes of Health recently reported that patients, such as Joshua Jacob Gonzalez, are experiencing remarkable improvements in their condition, marking a pivotal moment for the rare disease community. This…

Ongoing Cases